Search results
Showing 526 to 540 of 663 results for diabetes
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (IPG518)
We have moved interventional procedures guidance 518 to become HealthTech guidance 371. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Mental health of adults in contact with the criminal justice system (NG66)
This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This guidance has been updated and replaced by NICE indicator 274.
Diabetes: statins for primary prevention of CVD (40 years and over) (IND183)
This guidance has been updated and replaced by NICE indicator 275.
In development Reference number: GID-MT538 Expected publication date: TBC
In development Reference number: GID-TA11352 Expected publication date: TBC
Digital technologies for multidisciplinary weight management
In development Reference number: GID-HTE10077 Expected publication date: TBC
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)
Interventional procedures, IPG257 - Issued: April 2008 --> We have moved interventional procedures guidance 257 to become HealthTech guidance 165. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)
We have moved interventional procedures guidance 787 to become HealthTech guidance 721. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]
In development Reference number: GID-TA11377 Expected publication date: TBC